Analyst Research Report Snapshot

Title:

MAGFORCE - NANOTHERM STRATEGY ON TRACK

Price:

$10.00

Provider:

Edison Investment Research

Date:

10 Jul 2014

Pages:

1

Type:

AcrobatPDF

Companies referenced:

MF6G.DE

Available for Immediate Download
Summary:

MagForce’s strategy to increase uptake of its NanoTherm therapy is on track and progress has been made in both Europe and the US in line with expectations. In Europe the installed base of NanoActivators has increased and the first patient was enrolled into the post-marketing glioblastoma (GBM) study. In the US, a positive pre-submission meeting was held with the FDA, confirming that NanoTherm will be designated as a medical device. MagForce continues to target initial commercial NanoTherm sales by end 2014, in addition to annual revenues of €100-150m as the target of the late 2013 five-year plan. Our risk-adjusted valuation published in November 2013 is €197m or €8.2/share.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.